Drug Discovery & Development - March 10, 2011
iAdvantage Software, Inc., a leading solutions provider for managing development and pre-clinical life science studies, announced that BioTox Sciences (BTS), a GLP Contract Research Organization, headquartered in San Diego, California, is deploying the eStudy hosted solution to manage its GLP and Non-GLP preclinical/nonclinical studies.
In 2010, BioTox Sciences expanded its resources from people to facility to accommodate growing Sponsors' needs. The final challenge was selecting a software platform that would handle the different preclinical study types BTS conduct's today, yet flexible enough to meet the ever-changing needs they may encounter as they continue to grow.
"After weighing our options and careful due diligence, BioTox Sciences chose to implement eStudy, by iAdvantage Software," commented Tareq Abu-Nadi, BioTox Sciences, Business Development/Study Director. "eStudy will complement and streamline the study processes conducted at BTS by increasing productivity and speed of reporting while maintaining 21 CFR parts 58 and 11 compliance."
"eStudy's flexibility ensures that BTS Study Directors would be able to use eStudy on various projects and multiple species. Whether a typical 28 day toxicity study in rats or dogs, or a long term surgery study in NHPs, eStudy will be used to manage the study, capture the data and allow for on-demand reporting of results upon Sponsor request. This significant investment gives us the ability to produce complete study books in mere hours, and help Sponsors make key decisions on development of compounds and initiate more projects," concluded Abu-Nadi.
eStudy is a 100% web-based study management platform that iAdvantage Software hosts for BTS at Cegidem/Dendrite's world-class network operating center in Chesapeake, VA. "eStudy will continually grow with BioTox Sciences, easily adapt to new study-types, marry to BTS' operational work-flow and interface with 3rd party instruments and tools," stated Diana Michelotti, Director of Marketing and Sales for iAdvantage. "eStudy implemented for BTS, provides BTS with a custom fit solution without the start-from-scratch price."
Date: March 9, 2011
Source: iAdvantage Software, Inc.
In 2010, BioTox Sciences expanded its resources from people to facility to accommodate growing Sponsors' needs. The final challenge was selecting a software platform that would handle the different preclinical study types BTS conduct's today, yet flexible enough to meet the ever-changing needs they may encounter as they continue to grow.
"After weighing our options and careful due diligence, BioTox Sciences chose to implement eStudy, by iAdvantage Software," commented Tareq Abu-Nadi, BioTox Sciences, Business Development/Study Director. "eStudy will complement and streamline the study processes conducted at BTS by increasing productivity and speed of reporting while maintaining 21 CFR parts 58 and 11 compliance."
"eStudy's flexibility ensures that BTS Study Directors would be able to use eStudy on various projects and multiple species. Whether a typical 28 day toxicity study in rats or dogs, or a long term surgery study in NHPs, eStudy will be used to manage the study, capture the data and allow for on-demand reporting of results upon Sponsor request. This significant investment gives us the ability to produce complete study books in mere hours, and help Sponsors make key decisions on development of compounds and initiate more projects," concluded Abu-Nadi.
eStudy is a 100% web-based study management platform that iAdvantage Software hosts for BTS at Cegidem/Dendrite's world-class network operating center in Chesapeake, VA. "eStudy will continually grow with BioTox Sciences, easily adapt to new study-types, marry to BTS' operational work-flow and interface with 3rd party instruments and tools," stated Diana Michelotti, Director of Marketing and Sales for iAdvantage. "eStudy implemented for BTS, provides BTS with a custom fit solution without the start-from-scratch price."
Date: March 9, 2011
Source: iAdvantage Software, Inc.
No hay comentarios:
Publicar un comentario